Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Ares Trading S.A. currently manages 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 6 actions are assigned to 6 distinct examiners, meaning each matter is being reviewed by a different individual. The portfolio is spread across 6 distinct art units, matching the number of examiners and pending actions exactly.
TAYONG, HELENE E is the busiest examiner, holding 1 busiest examiner pending office action. This 1 action is one of the 6 pending office actions currently active. The presence of 6 distinct art units for 6 distinct examiners indicates that every pending case is located in a different USPTO department, which may result in a wide variety of examination perspectives.
The 6 pending office actions in Biotechnology & Pharmaceuticals represent a highly decentralized prosecution effort. Because there are 6 distinct examiners and 6 distinct art units, there is no commonality in the personnel or units reviewing the company's applications. The busiest examiner pending count of 1 highlights the even distribution of the workload across the 6 pending office actions, requiring a unique strategy for each case.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (50%) |
| §103 only | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TAYONG, HELENE E | 1 | 89.2% | +14.8% |
| BERA, HENA RAKESHKUMAR | 1 | 100.0% | +0.0% |
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
| D' AMBROSIO, THEA | 1 | 55.5% | +56.2% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.6% |
| ZEMAN, MARY K | 1 | 58.9% | +34.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18676669 | COMMUNICATION APPARATUS FOR USE WITH ELECTRONIC COMMUNICATION ELEMENT, ELECTRONIC COMMUNICATION ELEMENT AND USES THEREOF | TAYONG, HELENE E | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18023009 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | YOUNGBLOOD, WILLIAM JUSTIN | 34d |
| 18283939 | METHOD FOR GLYCOSYLATION PROFILING TO DESCRIBE FUNCTIONAL CHARACTERISTICS OF A BIOLOGIC MOLECULE | BERA, HENA RAKESHKUMAR | — |
| 18280340 | IMPROVED TREATMENT METHODS USING DMDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES, AND BIOMARKER FOR PREDICTING AND/OR OPTIMISING SAID TREATMENT METHODS | LEE, YIE CHIA | — |
| 18251534 | Combination Treatment of Cancer | D' AMBROSIO, THEA | — |
| 17968167 | METHOD FOR DETERMINING CELL CLONALITY | ZEMAN, MARY K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18023009 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | YOUNGBLOOD, WILLIAM JUSTIN | 34d |
| 18676669 | COMMUNICATION APPARATUS FOR USE WITH ELECTRONIC COMMUNICATION ELEMENT, ELECTRONIC COMMUNICATION ELEMENT AND USES THEREOF | TAYONG, HELENE E | — |
| 18280340 | IMPROVED TREATMENT METHODS USING DMDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES, AND BIOMARKER FOR PREDICTING AND/OR OPTIMISING SAID TREATMENT METHODS | LEE, YIE CHIA | — |
| 18251534 | Combination Treatment of Cancer | D' AMBROSIO, THEA | — |
| 17968167 | METHOD FOR DETERMINING CELL CLONALITY | ZEMAN, MARY K | — |
| Art Unit | Apps |
|---|---|
| 2631 | 1 |
| 1678 | 1 |
| 1644 | 1 |
| 1654 | 1 |
| 1629 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18676669 | COMMUNICATION APPARATUS FOR USE WITH ELECTRONIC COMMUNICATION ELEMENT, ELECTRONIC COMMUNICATION ELEMENT AND USES THEREOF | TAYONG, HELENE E | 2631 | §103 | Non-Final OA | — | Pending | May 29, 2024 |
| 18283939 | METHOD FOR GLYCOSYLATION PROFILING TO DESCRIBE FUNCTIONAL CHARACTERISTICS OF A BIOLOGIC MOLECULE | BERA, HENA RAKESHKUMAR | 1678 | §101§103 | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18280340 | IMPROVED TREATMENT METHODS USING DMDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES, AND BIOMARKER FOR PREDICTING AND/OR OPTIMISING SAID TREATMENT METHODS | LEE, YIE CHIA | 1644 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 05, 2023 |
| 18251534 | Combination Treatment of Cancer | D' AMBROSIO, THEA | 1654 | §103§112 | Non-Final OA | — | Pending | May 02, 2023 |
| 18023009 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §103§112 | Final Rejection | 34d | Pending | Feb 24, 2023 |
| 17968167 | METHOD FOR DETERMINING CELL CLONALITY | ZEMAN, MARY K | 1672 | §101§102§112Other | Non-Final OA | — | Pending | Oct 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAres Trading S.A. has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Helene E Tayong has the most, with 1 of Ares Trading S.A.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
